Cargando…
Combination treatment of rituximab and donor platelets infusion to reduce donor‐specific anti‐HLA antibodies for stem cells engraftment in haploidentical transplantation
BACKGROUND: Donor‐specific anti‐human leukocyte antigen (HLA) antibodies (DSAs) in recipients is a risk factor for donor stem cell graft failure in haploidentical hematopoietic stem cell transplantation (haplo‐HSCT), and the treatment to reduce the levels of DSAs is not unanimous. This study was to...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370703/ https://www.ncbi.nlm.nih.gov/pubmed/32112480 http://dx.doi.org/10.1002/jcla.23261 |